AHN, or MCL, after at least one systemic therapy. In December 2023, the European Commission approved AYVAKYT for the treatment of adult patients with indolent SM with moderate to severe symptoms inadequately controlled on symptomatic treatment. These approvals in advanced SM were supported by our ongoing Phase 1 clinical trial in advanced SM, which we refer to as our EXPLORER trial, and our ongoing Phase 2 clinical trial in advanced SM, which we refer to as our PATHFINDER trial. The FDA's approval of AYVAKI ...

Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Fouad Namouni - President-Research & Development Mike Landsittel - Chief Financial Officer Christy Rossi - Chief Operating Officer Becker Hewes - Chief Medical Officer Conference Call Participants Brad Canino - Stifel Marc Frahm - TD Cowen Laura Prendergast - R ...

First Quarter 2024 Financial Results Agenda AYVAKIT PERFORMANCE | --- | --- | --- | --- | --- | |-------|-------|-------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | Q1 2024 FINANCIAL | | | | | | PERFORMANCE | | | | | | | | | | | | | | | | | | Mike Landsittel | | | | | | Chief Financial Officer | | | 2 3 INTRODUCTION Kate Haviland Chief Executive Officer THE POWERFUL MAST CELL Not for promotional use Forward-looking statements This presentation contains forward-looking statem ...

Blueprint Medicines (BPMC) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to loss of $2.15 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 19.51%. A quarter ago, it was expected that this cancer drug developer would post a loss of $2.04 per share when it actually produced a loss of $1.82, delivering a surprise of 10.78%.Over the last four quarters, the co ...

Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance -- Raising guidance to $390 million to $410 million in full year AYVAKIT net product revenues -- -- Strengthening presence in allergy and inflammation with the IND for wild-type KIT inhibitor BLU-808 on track for filing in Q2 -- "We delivered another very strong quarter in our launch of AYVAKIT in indolent systemic mastocytosis (ISM) and have entered 2024 in a position of stren ...

-- Achieved $92.5 million in AYVAKIT net product revenues in the first quarter 2024 -- -- Raising guidance to $390 million to $410 million in full year AYVAKIT net product revenues -- -- Strengthening presence in allergy and inflammation with the IND for wild-type KIT inhibitor BLU-808 on track for filing in Q2 -- CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 202 ...

­-- Dr. Mariana Castells, M.D., Ph.D., a renowned researcher and clinical expert in mast cell diseases, will join members of Blueprint Medicines' management team to provide a perspective on the mast cell as a promising target for treating allergic and inflammatory disease on April 25, 2024, at 10:00 a.m. ET -- -- First in a series of planned webcasts hosted by Blueprint to highlight evolving science around R&D and pipeline strategy -- CAMBRIDGE, Mass., April 11, 2024 /PRNewswire/ -- Blueprint Medicines Corp ...

-- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable safety supporting long-term treatment, consistent with real-world experience observed in commercial setting -- -- Preclinical data for BLU-808, a highly selective and potent oral wild-type KIT inhibitor with best-in-class potential, supports development in chronic urticaria and other mast cell diseases; on track to submit IND to FDA in Q2 2024 -- -- Breadth of data across 9 presentations, including 2 oral, hi ...

Blueprint Medicines (BPMC) reported $71.96 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 85.6%. EPS of -$1.82 for the same period compares to -$2.65 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $67.28 million, representing a surprise of +6.95%. The company delivered an EPS surprise of +10.78%, with the consensus EPS estimate being -$2.04.While investors closely watch year-over-year changes in headline numbers -- revenue and e ...

Blueprint Medicines Corporation (BPMC) reported a fourth-quarter 2023 loss of $1.82 per share, narrower than the Zacks Consensus Estimate of a loss of $2.04 and a loss of $2.65 in the year-ago quarter.Quarterly revenues of $72.0 million also surpassed the Zacks Consensus Estimate of $67.3 million. Revenues rose 85.5% year over year.Quarter in DetailBlueprint’s total revenues comprise net product revenues from Ayvakit/Ayvakyt and collaboration revenues.Ayvakit (avapritinib), an inhibitor of KIT and PDGFRA pr ...